MktsMarkets

Pasithea Therapeutics Corp.
NASDAQ: KTTAKey statistics
KTTA News
Stories mentioning KTTA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,942 | 2,744 | 1,358 | 2,149 | 1,730 | 1,510 | 1,581 | 2,358 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (4,877) | (10,256) | (3,110) | (3,811) | (3,680) | (3,259) | (3,005) | (3,945) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (14.00) | 7.00 | 7.00 | 7.00 | 114.00 | |||
| Pretax Income | (2,869) | (10,112) | (3,037) | (3,716) | (3,563) | (3,178) | (3,000) | (3,866) |
| Tax Provision | ||||||||
| Net Income (Loss) | (2,869) | (10,112) | (3,037) | (3,716) | (3,563) | (3,178) | (3,000) | (3,866) |
| Earnings Per Share (Basic) | (0.12) | (1.44) | (0.41) | (0.66) | (1.61) | (2.90) | (2.87) | (3.71) |
| Earnings Per Share (Diluted) | (0.12) | (1.44) | (0.41) | (0.66) | (1.61) | (2.90) | (2.87) | (3.71) |
| Weighted Average Shares Outstanding (Basic) | 24,338 | 7,031 | 7,444 | 5,641 | 2,211 | 1,096 | 1,044 | 1,043 |
| Weighted Average Shares Outstanding (Diluted) | 24,338 | 7,031 | 7,444 | 5,641 | 2,211 | 1,096 | 1,044 | 1,043 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About KTTA
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a stock listed on the Nasdaq Stock Market under the ticker symbol KTTA. It last traded at $0.4500 (Nov 18, 2026, 10:06 AM ET), up 3.9% on the day. That gives Pasithea Therapeutics a market capitalisation of $16.0M.
Over the past 52 weeks KTTA has traded between $0.2800 and $2.06.
For the quarter ended Mar 31, 2026 it reported a net loss of $2.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$2.9M |
| Dec 31, 2025 | — | -$10.1M |
| Sep 30, 2025 | — | -$3.0M |
| Jun 30, 2025 | — | -$3.7M |
From Pasithea Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…